|
Thomas Hofmann, MD, Ph.D. Vice President, New Product Development. is responsible for the management of the Company's SRT clinical programs. Dr. Hofmann brings 16 years of experience in pediatrics and pulmonary medicine, including managing clinical trials for European and U.S. biopharmaceutical companies. Most recently, Dr. Hofmann held the position of Senior Medical Director at Corus Pharma Inc. and was a co-founder. At Corus, he was responsible for several late stage clinical development programs in respiratory and critical care medicine with a strong focus on Cystic Fibrosis, Asthma and Sleep Apnea. Prior to that, Dr. Hofmann was the Medical Director of Pulmopharm GmbH (acquired by Chiron) where he provided a significant contribution in the development and German approval of inhaled Tobramycin for Cystic Fibrosis. Dr. Hofmann has an extensive academic background and is a recognized scientist in the field of aerosol science and pulmonology, with a focus on Cystic Fibrosis. Dr. Hofmann received his Medical Degree and PhD in Electrophysiology from JLU Giessen in Germany and conducted postdoctoral research at the Cystic Fibrosis Center, University of North Carolina. | 